Rukaiah Fatma Begum

Rukaiah Fatma Begum

Auto-generated profile, based on publicly available information

Rukaiah Fatma Begum

Institute of Pharmaceutical Research GLA University Mathura Uttar Pradesh India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Future Science OA
Verified
Journal Article
Open access
ARAakash Ramanishankar
Aakash Ramanishankar
ASAnkul Singh S
Ankul Singh S
RBRukaiah F Begum
Rukaiah F Begum
NJNARAYANAN J
NARAYANAN J
ANAfreen Nayeem
Afreen Nayeem
NSNirenjen Shanmugasundaram
Nirenjen Shanmugasundaram
Aim: Photobiomodulation involves the use of low-level light therapy or near-infrared light therapy found to be useful in the treatment of a wide range of neurological diseases. Objective: The aim i... Plain language summary Alzheimer's disease (AD) is an incurable progressive neurodegenerative disease clinically manifested with a decline in cognitive function. To ensure that the consensus statem...

17 April 2024 in Future Science OA
Verified
Journal Article
Open access
RBRukaiah Fatma Begum
Rukaiah Fatma Begum
SMsumithra Mohan
sumithra Mohan
Aim: This study seeks to explore the possibility of using vitamin E to alleviate the symptoms of polycystic ovarian syndrome (PCOS). Methods: Various computational methods were employed, including ... Plain language summary Polycystic ovarian syndrome (PCOS) is a common condition that affects many girls and young women during their reproductive years. PCOS can lead to problems with the menstrual...

23 April 2024 in EXCLI Journal
Verified
Journal Article
Open access
RRRapuru Rushendran
Rapuru Rushendran
RBRukaiah Fatma Begum
Rukaiah Fatma Begum
ASAnkul Singh S
Ankul Singh S
PNPavithra Lakshmi Narayanan
Pavithra Lakshmi Narayanan
CVChitra Vellapandian
Chitra Vellapandian
PPPijush Kumar Paul
Pijush Kumar Paul
Novel treatments are needed as neurological issues become more frequent worldwide. According to the report, plants, oceans, microorganisms, and animals contain interesting drug discovery compounds. Alzheimer's, Parkinson's, and stroke reviews emphasize neurological disorders’ complexity and natural substances’ safety. Learn about marine-derived and herbal substances’ neuroprotective characteristics and applications. Molecular pathways show these substances’ neurological healing effects. This article discusses clinical usage of Bryostatin-1, Fucoidan, Icariin, Salvianolic acid, Curcumin, Resveratrol, etc. Their potential benefits for asthma and Alzheimer’s disease are complex. Although limited, the study promotes rigorous scientific research and collaboration between traditional and alternative medical practitioners. Unexplored natural compounds, quality control, well-structured clinical trials, and interdisciplinary collaboration should guide future study. Developing and employing natural chemicals to treat neurological illnesses requires ethical sourcing, sustainability, and public awareness. This detailed analysis covers natural chemicals’ current state, challenges, and opportunities in neurological disorder treatment.

21 May 2026 in Food Biomacromolecules
Verified
Journal Article
Open access
PDF file
SSSridevi Shanmugam
Sridevi Shanmugam
RBRukaiah Fatma Begum
Rukaiah Fatma Begum
NSNirenjen Shanmugasundaram
Nirenjen Shanmugasundaram
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
SSSuresh Ankul Singh
Suresh Ankul Singh
KRKesarla Rajesh
Kesarla Rajesh
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective on food‐grade proteins, lipids, and dietary fibers in CVDs. Here, food‐grade refers to nutritionally safe, regulatory‐compliant macronutrients incorporated into functional foods with defined physiological benefits. This review evaluates how these macronutrients target key CVD pathways. Food‐grade proteins release bioactive peptides with ACE‐inhibitory, lipid‐lowering, and endothelial‐protective effects. Functional lipids, particularly omega‐3 fatty acids and phytosterols, regulate lipid metabolism, stabilize atherosclerotic plaques, and reduce inflammation. Soluble dietary fibers such as β‐glucan, psyllium, and pectin lower cholesterol absorption, improve glycemic control, and modulate gut microbiota. Importantly, this review highlights synergistic and antagonistic interactions among these macronutrients within real food matrices, emphasizing their combined influence on digestion, bioavailability, and metabolic responses. Dose–response relationships and practical intake considerations are also discussed to bridge mechanistic insights with dietary applications. Collectively, this framework positions food‐grade macronutrients as interactive modulators of cardiovascular health rather than isolated components. Future research should focus on validating nutrient interactions, optimizing synergistic formulations, and establishing clinically effective intake thresholds.